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COMMENTARY
Does upregulated host cell receptor 
expression provide a link between bacterial 
adhesion and chronic respiratory disease?
Ronan F. O’Toole*, Shakti D. Shukla and Eugene H. Walters
Abstract 
Expression of the platelet-activating factor receptor is upregulated in the respiratory epithelium of smokers and 
chronic obstructive pulmonary disease patients. We have recently determined that increased expression of PAFr cor-
relates with higher levels of adhesion to human bronchial epithelial cells by non-typable Haemophilus influenzae and 
Streptococcus pneumoniae which are major bacterial pathogens in acute exacerbations of COPD. In addition, we found 
that a PAFr antagonist decreased the adhesion of both respiratory bacterial pathogens to non-cigarette exposure con-
trol levels. This highlights the possibility that epithelial receptors, that are upregulated in response to cigarette smoke, 
could be targeted to specifically block chronic bacterial infections of the lower respiratory tract. In this commentary, 
we explore the question of whether adhesion to a temporally-upregulated host receptor is a common event in 
chronic bacterial disease, and as such, could represent a putative therapeutic target for blocking infection by respira-
tory and other pathogens.
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Chronic obstructive pulmonary disease 
and platelet‑activating factor receptor
Lung disease remains a major cause of death globally 
after heart disease and stroke [1]. Bacterial infection of 
the respiratory tract drives a number of communicable 
diseases including pneumonia and tuberculosis, but also 
acute exacerbations (AE) of the non-communicable ill-
ness, chronic obstructive pulmonary disease (COPD). 
The first step in bacterial colonisation of the respira-
tory tract involves the binding of a bacterial adhesin to 
its cognate receptor presented on the surface of the host 
cell. Expression of the microbial receptors on host epi-
thelium is therefore, key to the establishment of a respira-
tory infection.
Non-typable Haemophilus influenzae (NTHi) and 
Streptococcus pneumoniae are the main bacterial spe-
cies involved in triggering AECOPD [2, 3]. The primary 
risk factor for the development of COPD is cigarette 
smoke [4, 5]. Expression of a G-protein coupled recep-
tor (GPCR) protein, Platelet-activating factor receptor 
(PAFr), is significantly up-regulated in the airway epithe-
lium of both the large and small airways in smokers and 
COPD patients [6, 7].
Adhesion of NTHi and S. pneumoniae 
to upregulated bronchial epithelial PAFr
In a new publication, we report that attachment of both 
NTHi and S. pneumoniae to bronchial epithelial cells 
is enhanced by exposure to cigarette smoke extract [8]. 
We identified that the increased bacterial adherence cor-
related with upregulation of expression of PAFr on the 
surface of the lung epithelial cells [8]. PAFr is known to 
bind to phosphorylcholine which is a component of the 
cell wall of the above bacterial species and is a molecu-
lar mimic of human platelet-activating factor [9]. While 
host receptors are often regarded as being available per-
petually for bacterial adhesion, it is apparent from our 
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which is temporally-upregulated in response to a spe-
cific external stimulus, in this case, tobacco smoke. We 
also determined that a PAFr antagonist, WEB-2086 (Apa-
fant), reduced the adhesion of both respiratory bacterial 
pathogens down to non-cigarette exposure control levels 
[8]. This highlights the possibility that host surface recep-
tors, that are upregulated in response to cigarette smoke, 
could be targeted to specifically block chronic infec-
tions of the lower respiratory tract by both NTHi and S. 
pneumoniae.
Role of PAFr and the effects of PAFr antagonism
PAFr, when bound to its natural ligand, platelet activat-
ing factor (PAF), has been implicated in the pathophysi-
ology of anaphylaxis, bronchial hyper-responsiveness, 
endotoxin shock, respiratory bacterial infections, skin 
diseases, and disorders of the central nervous system 
[10]. In addition to blocking PAFr-mediated signaling, 
a number of PAFr-antagonists have been reported to 
inhibit enzymes such as acetylcholinesterase [11], and 
both cyclooxygenase and lipoxygenase [12], thus, dis-
rupting the inflammatory cascade. Long-term admin-
istration of a PAFr-antagonist (L659989) significantly 
delayed the onset of proteinuria and improved survival in 
a mouse model of glomerulonephritis [13]. Clinical trials 
in humans, primarily focused on asthma, have been per-
formed with PAFr antagonists. SR27417 inhibited PAF-
induced symptoms (coughing and dyspnoea) in asthma 
patients with only minor side effects [14]. Similarly, PAF 
analogue CV-3988, was not associated with any major 
adverse events in humans at doses of 750–2000  μg/kg 
[15]. In terms of returning to pre-treatment levels, no 
clinically evident adverse effects were reported for PAFr 
antagonist BN52021 nearly one year after a clinical trial 
in asthmatic children [16].
Alternate examples of temporally‑induced 
receptors for bacterial adhesion
Use of a non-constitutively expressed surface receptor for 
colonisation appears to be opportunistic. The question 
therefore arises: Is this phenomenon unique to PAFr and 
respiratory pathogens NTHi and S. pneumoniae?
Some strains of Pseudomonas aeruginosa, a major 
bacterial pathogen in cystic fibrosis, also express ChoP 
[17]. Infection of A549 human airway epithelial cells 
and mouse lungs with ExoU-expressing P. aeruginosa 
results in upregulation of PAFr expression which is 
inhibited in the presence of PAFr antagonist WEB-
2086 [18]. Instances of upregulation of other receptors 
of microbial adhesion on host cells can also be found. 
For example, NTHi stimulates expression of intercel-
lular adhesion molecule 1 (ICAM-1) on respiratory 
epithelial cells in an inoculum-dependent manner [19, 
20]. ICAM-1 in turn is a receptor for NTHi adhesion 
and therefore, NTHi appears to upregulate the expres-
sion of its own receptor. In relation to the digestive sys-
tem, a similar mechanism is observed with respect to 
induction of expression by Crohn’s Disease-associated 
Escherichia coli of its own ileal epithelial cell receptor, 
carcinoembryonic antigen-related cell adhesion mol-
ecule 6 (CEACAM6) [21].
It is also evident that infection by one pathogen can 
increase the level of a receptor available for another 
pathogen. For example, it was reported recently that 
influenza A viral (IAV) infection of human lung epi-
thelial cells results in heightened expression of cellular 
adhesins which in turn promotes streptococcal infection 
[22]. A previously unrecognised mechanism was identi-
fied in which IAV neuraminidase was found to promote 
the expression of fibronectin and α5 integrin through 
the activation of transforming growth factor beta (TGF-
β) leading to increased adhesion to respiratory epithe-
lial cells by Streptococcus pyogenes [22]. Thus, influenza 
infection effectively “primes” the respiratory epithelium 
for subsequent colonisation by Group A Streptococci by 
enhancing receptor presentation.
In a similar manner, respiratory syncytial virus (RSV) 
infection of respiratory epithelial cells has been shown to 
elevate the expression of ICAM-1, PAFr and CEACAM1, 
which correlated with increased adhesion of NTHi and 
S. pneumoniae [23]. NTHi binding to the lung epithelial 
cells was inhibited by the addition of either anti-ICAM-1 
or anti-PAFr antibodies, while adhesion of S. pneumoniae 
was blocked in the presence of anti-PAFr antibodies [23]. 
An additional surface receptor which may be presented 
during RSV infection consists of the RSV-encoded G gly-
coprotein which, when artificially expressed in respira-
tory epithelial cells, increased adherence by NTHi and 
S. pneumoniae [24]. Rhinovirus infection has also been 
shown to significantly increase fibronectin, PAFr and 
CEACAM expression in nasal epithelial cells correlating 
with augmented adhesion of S. aureus, S. pneumoniae, 
and H. influenzae [25]. The upregulation of PAFr expres-
sion due to rhinovirus infection of respiratory epithelial 
cells is mediated by the nuclear transcription factor-κB 
(NFκB) [26]. It has been suggested that the elevated PAFr 
expression in airway epithelial cells due to viral infection 
may contribute to the development of pneumonia after 
rhinovirus infection [26]. Furthermore, with approxi-
mately 25 % of acute exacerbations of COPD (AECOPD) 
exhibiting viral/bacterial co-infection [27], viral induc-
tion of bacterial receptor presentation on respiratory 
epithelium could potentially play a role in bacterial colo-
nisation during AECOPD.
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Conclusions and future perspectives
Our recent findings [8] should be examined in the con-
text of their translation into new ways to manage lung 
illnesses caused by bacterial infection. Given its up-
regulation in the respiratory epithelium in response to 
cigarette smoke and viral infection, PAFr represents a 
putative anti-infective target for therapeutics against 
AECOPD, and pneumonia, caused by NTHi or S. pneu-
moniae. PAFr antagonists including WEB-2086 are well 
tolerated [28–30] and therefore, provide chemical scaf-
folds for the synthesis of new classes of antibacterial 
drugs. The upregulation of bacterial epithelial recep-
tors is not unique to cigarette exposure but is also seen 
following infection with a number of viral respiratory 
pathogens including influenza, RSV and rhinovirus. It is 
therefore apparent that bacterial pathogens can “abduct” 
the upregulation of specific epithelial cell receptors for 
their adhesion, with the effect that it boosts their infectiv-
ity at a preferred host site, including the respiratory tract. 
Other receptor targets such as CAECAM and ICAM-1 
should also be examined with regard to the generation of 
new anti-infective agents for the treatment of AECOPD 
and pneumonia.
In conclusion, blocking adhesion to temporally upreg-
ulated host cell receptors may offer a basis for develop-
ing drugs that prevent infection by respiratory and other 
pathogens following exposure to insults such as viral 
infection or cigarette smoking.
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